- Home
- GNLX
GNLX
Genelux Corporation
as 11-21-2024 4:00pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 103.6M | IPO Year: | 2023 |
| Target Price: | $18.25 | AVG Volume (30 days): | 177.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $16.60 | Next Earning Date: | 11-14-2024 |
| Revenue: | $8,000 | Revenue Growth: | -96.64% |
| Revenue Growth (this year): | -97.6% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Genelux Corporation (GNLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Szalay Aladar | GNLX | 10% Owner | Sep 12 '24 | Sell | $2.65 | 64,857 | $171,678.28 | 632,901 | |
| Tyree James L | GNLX | Director | Sep 11 '24 | Sell | $2.60 | 1,730 | $4,498.87 | 47,521 | |
| Szalay Aladar | GNLX | 10% Owner | Sep 9 '24 | Sell | $2.61 | 75,143 | $196,608.84 | 632,901 | |
| Szalay Aladar | GNLX | 10% Owner | Sep 3 '24 | Sell | $2.09 | 42,818 | $89,613.79 | 632,901 | |
| Szalay Aladar | GNLX | 10% Owner | Aug 28 '24 | Sell | $2.07 | 265,552 | $554,410.54 | 632,901 | |
| Szalay Aladar | GNLX | 10% Owner | Aug 23 '24 | Sell | $2.20 | 91,630 | $200,277.85 | 632,901 |
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
GlobeNewswire
7 days ago
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
GlobeNewswire
15 days ago
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Simply Wall St.
21 days ago
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
MT Newswires
24 days ago
Guggenheim Initiates Genelux at Buy With $8 Price Target
GuruFocus.com
a month ago
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
Clinical Trials Arena
a month ago
Genelux doses first subject in Phase II trial of NSCLC treatment
GlobeNewswire
a month ago
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
Compare GNLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.